Last mentioned: Mar 6, 2026
Strategic Update
COSCIENS announces cessation of funding for German subsidiaries and expected insolvency.
FDA Type C Meeting
Company meets with FDA to discuss disappointing DETECT trial results and pediatric path forward.
DETECT Trial Results
Phase 3 trial for Macrilen pediatric indication fails to meet primary endpoints.
Wuzhou Distribution Deal
COSCIENS signs distribution agreement with Wuzhou Drug International Trading Limited.
COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.
This page surfaces every story mentioning COSCIENS Biopharma Inc. across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where COSCIENS Biopharma Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |